针药结合促排卵在辅助生育技术中的优势

文章从排卵障碍性不孕症的病因病机,中药调节月经周期,针灸治疗几个方面,综述了针药结合促排卵的临床研究进展,说明针药结合治疗排卵障碍引起的不孕的疗效明显优于单纯西医、中药治疗,其副作用小,在辅助生育技术(ART)中应用前景广阔,不仅降低了促排卵西药而致卵巢过度刺激征(OHSS)的风险,同时弥补了单纯中药见效慢的不足。     

Quality Control Approaches for Chinese Herbal Medicines

The current official quality control approaches meet the challenges from the complexity of herbal medicines. In fact, any herbal medicines containing numerous unknown components, its curative effect usually depends on the whole of herbal medicines, so it is impossible and unnecessary to qualitatively and quantitatively study every component. By investigating the limitations of current quality control approaches for herbal medicines and the difference and similarity in the chemical substantial style as well as quality control pattern of herbal medicines, a new quality control approach for Chinese herbal medicines should be explored and designed. The combination approach of chemical analysis with bioassay is promising to be developed and employed in order to ensure the safety and efficacy of Chinese herbal medicines.     

基于组合模型的交通流量预测方法

随着智能交通系统的蓬勃发展,交通控制和交通流诱导成为智能交通系统(ITS)研究的热门问题,而实现交通控制诱导的关键问题是实时准确的短时交通流量预测,预测的精度直接影响交通控制和诱导的效果。为此,提出基于组合模型的交通流量预测方法,该方法将历史趋势模型和多元回归模型加权组合以建立组合预测模型,并利用加权平均的方法,对较精确的预测值赋予较大的权重,从而提高模型预测的精度。通过对2009年上海城市交通流量预测结果的分析,证明该方法可提高预测准确度。     

降脂治疗潜在改善稳定型冠心病患者短暂性心肌缺血发作——DUAAL研究启示

1 文献来源 Deanfield JE, Sellier P, Thaulow E, et al. Potent anti-ischaemic effects of statins inchronic stable angina： Incremental benefit beyond lipid lowering.9 [J]. Eur Heart J, 2010,31 （21） ： 2650-2659.     

合用氟喹诺酮类药物对金黄色葡萄球菌突变选择窗的影响

[目的]探讨FQ药物联合用药对金黄色葡萄球菌突变选择窗(MSW)的影响.[方法]采用琼脂二倍稀释法测定3种药物对38株临床分离金黄色葡萄球菌株和金黄色葡萄球菌质控菌株ATCC25923的最低抑菌浓度(MIC)以及两种FQ的防突变浓度(MPC),计算FQ单药和联合用药后的MPC50、MPC90、MPC/MIC[选择指数(...     

磷霉素与9种抗菌药物分别联用对不动杆菌的体外抗菌活性研究

[目的]研究磷霉素与其它9种临床常用抗菌药物分别联合应用对47株不动杆菌的体外抗菌活性.[方法]收集痰标本中分离出的不动杆菌47株,将磷霉素与其它9种抗菌药物在体外单独以及联合应用,采用琼脂二倍稀释法,测定最低抑菌浓度(MIC)、计算部分抑菌浓度(FIC)指数,评价磷霉素与其它9种抗菌药物分别联合应用的体外抗菌活性.[...     

抗丙肝病毒药物研发的最新进展

丙型肝炎病毒(HCV)是引起慢性肝脏疾病的主要病因.目前尚无疫苗预防HCV感染.长效聚乙二醇Ⅰ型干扰素(pegIFN-α)和利巴韦林(RBV)联合应用是近十年来治疗丙肝的最佳药物,但仍有一半以上基因1型HCV感染者对该联合抗病毒治疗无效,并且IFN和RBV的毒副作用较大且疗程长达1年,因此极大地限制了其在临床上的应用....     

Reciprocal coordination of a combination oral contraceptive containing desogestrel+ethinyl estradiol on the expression of LOX-1 and LDLR in placental trophoblast cells

Background

The aim of this study was to assess the consistency of antiatherosclerotic potential of a combination oral contraceptive steroid (ethinyl estradiol+desogestrel) by rating its effect on the differential expression of the low-density lipoprotein receptor (LDLR) and lectin-like oxidized LDL (LOX-1) receptor.

Study Design

Cells from placental trophoblast cell line (JAR) and differentiated primary placental trophoblast cells isolated from term human placentae were used for this study. Expressions of LOX-1 and LDLR were assessed by immunoblot and immunocytochemistry assays. Differential effects of the constituent steroids in the combination of ethinyl estradiol and desogestrel were verified on the expression profile of the receptors.

Results

Desogestrel opposed the effect of ethinyl estradiol on LOX-1 expression, and when used in combination, the combination oral contraceptive reduced the expression of LOX-1 in contrast to LDLR. The characteristic change in the expressions of LOX-1 and LDLR showed an antiatherosclerotic improvisation at the unique combination of ethinyl estradiol (10 ng/mL) and desogestrel (20 ng/mL).

Conclusion

The aforesaid combination of ethinyl estradiol and desogestrel keeps LOX-1 and LDLR reciprocally expressed in antiatherosclerotic mode.     

评估以泮托拉唑为基础的三联和四联疗法根除幽门螺杆菌的疗效

目的 比较以泮托拉唑为基础的7d标准三联疗法与泮托拉唑+铋剂+甲硝唑+四环素的10 d四联疗法根除Hp的疗效和安全性.方法 170例非溃疡性消化不良的Hp感染者随机入选三联、四联治疗组.三联治疗组实行PAC方案:泮托拉唑40 mg(2次/d)+阿莫西林1.0 g(2次/d)+克拉霉素500 mg(2次/d),口服7 d.四联治疗组实行PBMT方案:泮托拉唑40 mg(2次/d)+胶体次枸橼酸铋220 mg(2次/d)+四环素750 mg(2次/d)+甲硝唑400 mg(2次/d),口服10 d.治疗结束后至少停药4周后复查13C-尿素呼气试验,结果≤4%.为Hp阴性,表示根除成功.同时评估疗效及安全性.结果 166例患者按方案完成治疗.三联治疗组按意图治疗分析(ITT)根除率为63.53%(54/85),较四联治疗组低[89.41%(76/85),x2=17.168,P=0.000].三联治疗组按实验方案分析(PP)根除率为65.06%(54/83),亦较四联治疗组低[91.57%(76/83),x2=13.588,P=0.000].从年龄段分析,年龄＞30岁者三联治疗组根除失败率为22.22%(4/18),较四联治疗组高[3.84%(1/26),x2=19.884,P=0.000].三联和四联治疗组不良反应发生率分别为60.00%(51/85)和42.35%(36/85).结论 在7 d标准三联疗法Hp根除疗效降低的情况下,含泮托拉唑、铋剂、四环素和甲硝唑的10 d四联方案可考虑为首选方案.

Abstract：

Objective Compare the efficacy and safety of pantoprazole-based 7-day standard triple therapy with 10-day quadruple therapy including pantoprazole, bismuth, metronidazole and tetracycline in Helicobacter pylori (H.pylori) eradication.Methods A total of 170 H.pylori positive patients with non-ulcer dyspepsia were recruited and randomly assigned into triple and quadruple therapy groups.The triple therapy group was implemented with PAC program which included orally taking pantoprazole 40 mg twice per day, amoxicillin 1.0 g twice per day and clarithromycin 500 mg twice per day for seven days.The quadruple therapy group was implemented with PBMT program which consisted of orally taking pantoprazole 40 mg twice per day, colloidal bismuth subcitrate 220 mg twice per day, metronidazole 400 mg three times per day and tetracycline 750 mg twice per day for ten days.The 13C -urea breathe test was re-examined at least 4 weeks after the completion of treatment, the result lower than 4%.was H.pylori negative which indicated the success of H.pylori eradication.The efficacy and safety were also evaluated.Results A total of 166 patients completed the treatment.With intention-to-treat (ITT) analysis, the H.pylori eradication rate in the triple therapy group was 63.5% (54/85), lower than that of the quadruple therapy group (89.41%(76/85) ,x2= 17.168,P=0.000).With per protocol (PP) analysis, the eradication rate in the triple therapy group was 65.06% (54/83), also lower than that of the quadruple therapy group (91.57 % (76/83) ,x2 = 13.588 ,P=0.000).Through the age analysis, in patients over 30 years old,the eradication failed rate in the triple therapy group was 22.22% (4/18), higher than that of the quadruple therapy group (3.84% (1 / 26), x2 = 19.884, P=0.000).The incidence of adverse reaction rates of the triple and quadruple therapy group were 60.00% (51/85) and 42.35 % (36/85) respectively.Conclusion Since the reduction of eradication rate with seven day standard triple therapy,the 10-day pantoprazole, bismuth, metronidazole and tetracycline quadruple therapy may be considered as the first choice.     

症状性脑动脉狭窄未行支架植入患者多类药物一体化治疗的研究

目的探讨症状性脑动脉狭窄未行支架植入患者多类药物一体化治疗方案的效果、终点事件及安全性。方法初发的症状性脑动脉狭窄患者1 126例,随机分为治疗组787例,对照组339例。治疗组给予个体化分层血压调治技术,联合抗血小板及分层下调治血糖、血脂、纤维蛋白原的多类药物小剂量一体化协同治疗。对照组给予降压、单纯阿司匹林抗血小板、降糖、降脂、降纤的治疗方案。比较两组治疗后3年和5年健康功能水平、责任颈动脉狭窄区斑块内部回声特征、终点事件、不良反应、依从性情况。结果治疗组3年和5年脑梗死发生和复发、心脏事件、出血性表现、低血糖的发生率均明显低于对照组6.0%vs 13.3%、9.5%vs 19.2%、5.8%vs 12.4%、1.9%vs 6.2%、2.3%vs 7.1%（P〈0.01）。治疗组3年和5年健康功能水平均高于对照组（P〈0.05）;超声复查斑块均较对照组稳定（P〈0.05）;治疗后5年病死率低于对照组4.2%vs 7.4%（P〈0.05）。两组头痛发生率差异有统计学意义（P〈0.05）。对照组退出率高于治疗组13.6%vs 5.3%（P〈0.01）。结论症状性脑动脉狭窄未行支架植入患者多类药物一体化治疗方案显著降低了脑梗死发生和复发、心脏事件、出血性表现和低血糖的不良反应,极大提高了功能健康水平,效果显著,使用安全,患者依从性好。